Andrès E, Maloisel F
Service de Médecine Interne, Clinique Médicale B, Hôpitaux Universitaires de Strasbourg, France.
Rev Med Interne. 2006 Mar;27(3):209-14. doi: 10.1016/j.revmed.2005.06.008. Epub 2005 Jul 25.
Agranulocytosis is a life-threatening disorder that frequently occurs as an adverse reaction to drugs.
Idiosyncratic drug-induced agranulocytosis is characterized by a neutrophil count <0.5x10(9)/l, in serious forms <0,1x10(9)/l that currently occurs especially in association with antibiotics, antithyroid drugs ant ticlopidine (>60% of the incriminated drugs). The overall incidence of idiosyncratic agranulocytosis ranges from 2.4 to 15.4 cases per million patients exposed to drugs per year. Although patients experiencing idiosyncratic agranulocytosis may be asymptomatic (50%), the severity of the neutropenia usually leads to severe sepsis: fever of unknown origin, septicemia, septic shock or localized documented infections such as sore throat, various cutaneous infections or pneumonia. Nevertheless, the mortality rate of idiosyncratic agranulocytosis is now around 5% with appropriate management.
In the future, management of drug-induced agranulocytosis may include pre-established procedures using in critically situations, broad-spectrum antibiotic therapy and hematopoietic growth factors (G-CSF).
粒细胞缺乏症是一种危及生命的疾病,常作为药物不良反应出现。
特异性药物诱导的粒细胞缺乏症的特征是中性粒细胞计数<0.5×10⁹/L,严重形式下<0.1×10⁹/L,目前尤其与抗生素、抗甲状腺药物及噻氯匹定(>60%的相关药物)有关。特异性粒细胞缺乏症的总体发病率为每年每百万暴露于药物的患者中有2.4至15.4例。尽管发生特异性粒细胞缺乏症的患者可能无症状(50%),但中性粒细胞减少的严重程度通常会导致严重脓毒症:不明原因发热、败血症、感染性休克或局部确诊感染,如喉咙痛、各种皮肤感染或肺炎。然而,通过适当管理,特异性粒细胞缺乏症的死亡率目前约为5%。
未来,药物诱导的粒细胞缺乏症的管理可能包括在危急情况下使用预先制定的程序、广谱抗生素治疗和造血生长因子(G-CSF)。